Preference for a Prefilled Syringe or Smartject™ Device for Delivering Golimumab in Participants Suffering From Moderate-to-severe Ulcerative Colitis (MK-8259-027)

NCT02155335 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Ulcerative Colitis

Interventions

DRUG: Prefilled Syringe delivery of Golimumab
DRUG: Smartject Device delivery of Golimumab

Sponsor

Merck Sharp & Dohme LLC